Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk (NVO) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by March 25 Deadline
New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
World Trademark Review8h
USPTO mass resignation concerns; INPI president interview; WTR summit speaker line-up; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...
Two U.S. senators slammed an S.F. telehealth company’s Super Bowl ad. Here’s why
A San Francisco online health company that recently faced local backlash over its donation to President Donald Trump’s inauguration is now in hot water over a Super Bowl ad. Hims & Hers, a telehealth ...
pharmaphorum19h
Novo Nordisk steps up sickle cell push with $1.1bn Forma buy
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...